Bristol Myers Squibb (BMY) versus Its Peers Critical Contrast

Bristol Myers Squibb (NYSE:BMY) is one of 897 publicly-traded companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its competitors? We will compare Bristol Myers Squibb to related companies based on the strength of its dividends, risk, valuation, institutional ownership, analyst recommendations, earnings and profitability.

Profitability

This table compares Bristol Myers Squibb and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bristol Myers Squibb	18.87%	66.90%	14.74%
Bristol Myers Squibb Competitors	-2,380.63%	-221.06%	-16.01%

Earnings & Valuation

This table compares Bristol Myers Squibb and its competitors revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Bristol Myers Squibb	$48.19 billion	$7.05 billion	13.76
Bristol Myers Squibb Competitors	$3.54 billion	$3.18 billion	545.61

Bristol Myers Squibb has higher revenue and earnings than its competitors. Bristol Myers Squibb is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Bristol Myers Squibb and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bristol Myers Squibb	1	16	11	2	2.47
Bristol Myers Squibb Competitors	7752	13841	25683	1031	2.41

Bristol Myers Squibb currently has a consensus target price of $65.46, suggesting a potential upside of 4.77%. As a group, “Pharmaceuticals” companies have a potential upside of 23.94%. Given Bristol Myers Squibb’s competitors higher possible upside, analysts clearly believe Bristol Myers Squibb has less favorable growth aspects than its competitors.

Institutional & Insider Ownership

76.4% of Bristol Myers Squibb shares are held by institutional investors. Comparatively, 32.4% of shares of all “Pharmaceuticals” companies are held by institutional investors. 0.1% of Bristol Myers Squibb shares are held by company insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Dividends

Bristol Myers Squibb pays an annual dividend of $2.52 per share and has a dividend yield of 4.0%. Bristol Myers Squibb pays out 55.5% of its earnings in the form of a dividend. As a group, “Pharmaceuticals” companies pay a dividend yield of 3.3% and pay out 48.3% of their earnings in the form of a dividend. Bristol Myers Squibb has raised its dividend for 17 consecutive years.

Volatility and Risk

Bristol Myers Squibb has a beta of 0.19, meaning that its stock price is 81% less volatile than the S&P 500. Comparatively, Bristol Myers Squibb’s competitors have a beta of -4.34, meaning that their average stock price is 534% less volatile than the S&P 500.

Summary

Bristol Myers Squibb beats its competitors on 10 of the 15 factors compared.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.